Search articles in Pharma Appointments

Found 633 articles

  • Vedanta Biosciences Appoints Simona Levi as Chief

    Vedanta Biosciences Appoints Simona Levi as Chief Legal Officer and Corporate Secretary

    • 14 Oct 2021
    • Editor

    Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced the appointment of Simona Levi, Ph.D., J.D., as Chief Legal Officer and Corporate Secretary.

  • MiNA Therapeutics expands senior leadership team w

    MiNA Therapeutics expands senior leadership team with four new hires to support next phase of growth

    • 13 Oct 2021
    • Editor

    MiNA Therapeutics Limited (“MiNA” or the “Company”), the pioneer in small activating RNA (saRNA) therapeutics, announces that it has significantly expanded its senior leadership team with four new appointments to support the Company’s next phase of growth.

  • Vifor Pharma announces changes to its Executive Co

    Vifor Pharma announces changes to its Executive Committee

    • 13 Oct 2021
    • Editor

    Vifor Pharma Group today announced changes to its Executive Committee as current members Lee Heeson, President International, and Gregory Oakes, President North America, have decided to leave the company for personal reasons. Succession planning is currently underway and will be announced once the process has been concluded.

  • Bone Therapeutics appoints Scientific Advisory Boa

    Bone Therapeutics appoints Scientific Advisory Board for iMSC cell and gene therapy platform development

    • 13 Oct 2021
    • Editor

    BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), a cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces it has appointed key experts to a Scientific Advisory Board (SAB). Bone Therapeutics has appointed the members of this SAB specifically to provide additional expert guidance on the development of Bone Therapeutics’ novel, next generation iMSC platform.

  • Coave Therapeutics appoints Olivier Danos and Fred

    Coave Therapeutics appoints Olivier Danos and Frederic Chereau as non-executive directors to its Board

    • 13 Oct 2021
    • Editor

    Coave Therapeutics (‘Coave’), a clinical-stage biotechnology company focused on developing life-changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases, announces the appointment of Dr. Olivier Danos PhD and Frederic Chereau MBA to the Company’s Board of Directors, as independent non-executive directors. Olivier Danos is also appointed Scientific Advisor to the company.

  • Dr Richard Turkington Joins Almac Diagnostic Servi

    Dr Richard Turkington Joins Almac Diagnostic Services to Support Biomarker Research

    • 7 Oct 2021
    • Editor

    Almac Diagnostic Services is delighted to announce Dr Richard Turkington has joined its management team as UK Medical Director to further support biomarker research and clinical trial delivery. Bringing together academia, industry and healthcare stakeholders, this unique collaboration creates alignment of academic insight and industrial capability in the field of personalised medicine.

  • Oculis Appoints Dr. Joanne Chang as Global Chief M

    Oculis Appoints Dr. Joanne Chang as Global Chief Medical Officer and Opens Hong Kong Office to broaden its footprint and build a strong Asia/China presence

    • 7 Oct 2021
    • Editor

    Oculis S.A., (Oculis) a late-stage biopharmaceutical company focused on developing transformative ophthalmic treatments to improve the sight and lives of patients, announces the appointment of Dr. Joanne Chang, M.D., Ph.D., as Chief Medical Officer and Head of Portfolio Management.

  • HealthCap Strengthens Senior Team

    HealthCap Strengthens Senior Team

    • 7 Oct 2021
    • Editor

    HealthCap, a leading European life sciences venture capital firm, is delighted to announce that Dr. Mårten Steen, MD, PhD, has been appointed Co-Managing Partner alongside Founding Partner Björn Odlander. Mårten became a Partner at HealthCap in 2010 and has been instrumental in many of HealthCap´s most successful investments including Ultragenyx and Wilson Therapeutics.

  • Heiner Dreismann Joins Noscendo’s Board of Directo

    Heiner Dreismann Joins Noscendo’s Board of Directors

    • 6 Oct 2021
    • Editor

    Noscendo GmbH, a leading diagnostic company for identification and assessment of bloodstream associated pathogens and other infections announced today the addition of Heiner Dreismann, former President and CEO of Roche Molecular Systems, to its Board of Directors.

  • Gisèle Deblandre Joins Cellbox Solutions as CSO

    Gisèle Deblandre Joins Cellbox Solutions as CSO

    • 6 Oct 2021
    • Editor

    Cellbox Solutions GmbH has recruited Dr. Gisèle Deblandre to the team. The well-known industry expert joins the biotechnology company as Chief Scientific Officer (CSO) effective today. With her extensive knowledge in the development of manufacturing processes and analytical methods for cell-based therapies and ex-vivo gene therapies, Deblandre will be responsible for the Cell & Gene Therapy division and successfully develop this market for Cellbox Solutions.

  • Adrestia Therapeutics announces appointment of Dr

    Adrestia Therapeutics announces appointment of Dr Tom D. Heightman as Chief R&D Officer

    • 6 Oct 2021
    • Editor

    Adrestia Therapeutics, a UK-based biotechnology company using cutting edge cell and molecular biology to develop precision medicines, announces the appointment of Dr Tom D. Heightman as Chief R&D Officer. Tom is a leading medicinal chemist with broad experience of drug discovery, and over his 23-year career has implemented transformative innovation in drug discovery and delivered multiple programs into the clinic.

  • ProQR Appoints Theresa Heggie as Chief Commercial

    ProQR Appoints Theresa Heggie as Chief Commercial Officer

    • 5 Oct 2021
    • Editor

    ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced the appointment of Theresa Heggie as Chief Commercial Officer reporting to Daniel de Boer, Founder and CEO.

  • Centessa Pharmaceuticals Appoints David Grainger,

    Centessa Pharmaceuticals Appoints David Grainger, PhD, a Leading Biotech Entrepreneur, as Chief Innovation Officer

    • 5 Oct 2021
    • Editor

    Centessa Pharmaceuticals plc (“Company”) (Nasdaq: CNTA), a clinical-stage company leveraging its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients, today announced that David Grainger, PhD, has been appointed to the newly-created role of Chief Innovation Officer.

  • Merck Announces Appointment of Thomas H. Glocer as

    Merck Announces Appointment of Thomas H. Glocer as Independent Lead Director

    • 30 Sep 2021
    • Editor

    Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the independent members of the Merck Board of Directors have appointed Thomas H. Glocer as independent lead director effective immediately. Mr. Glocer has served on the Merck Board of Directors since 2007. He has extensive management, operational, technology and international business expertise, including his history of accomplishment and executive leadership.

  • Announcing Our New Communications CEO, Margot Hann

    Announcing Our New Communications CEO, Margot Hannah

    • 29 Sep 2021
    • Editor

    OPEN Health is pleased to announce the appointment of Margot Hannah as the new Chief Executive Officer of OPEN Health Communications. Since joining OPEN Health in 2011, Margot has provided tremendous leadership and dedication to the company. She has held numerous positions, most recently as President of the Medical Communications Center of Excellence, where she has been instrumental in building a high-performance team by developing and retaining best-in-class talent.

  • Prof. René Schenkendorf joins Insilico Biotechnolo

    Prof. René Schenkendorf joins Insilico Biotechnology AG Scientific Advisory Board

    • 29 Sep 2021
    • Editor

    Insilico Biotechnology AG has announced that Prof. Dr.-Ing. René Schenkendorf has complemented its Scientific Advisory Board. With this further expansion of the board Insilico will be prepared to face the challenges presented by the high demand for biopharma digitalization.

  • Delta 4 Announces Dr. Hans Lehrach to Join Scienti

    Delta 4 Announces Dr. Hans Lehrach to Join Scientific Advisory Board

    • 29 Sep 2021
    • Editor

    Delta 4, a digital drug discovery company focusing on the identification of new indications for existing drug compounds, today announced that Dr. Hans Lehrach will join its Scientific Advisory Board. Prof. Lehrach is a distinguished scientist in the area of genomics.

  • Enara Bio announces the appointment of highly expe

    Enara Bio announces the appointment of highly experienced biotech executive Dr. Robert Ang to its Board of Directors

    • 29 Sep 2021
    • Editor

    Enara Bio, a biotechnology company advancing novel T-cell receptor (TCR) directed immunotherapies against unconventional, shared, cancer-specific antigens, announces the appointment of Dr. Robert Ang to the Company’s Board of Directors as an independent non-executive director.

  • LovedBy hires former AXA Health executive as Clini

    LovedBy hires former AXA Health executive as Clinical Director

    • 22 Sep 2021
    • Editor

    LovedBy, a technology and consultancy business that exists to improve the lives of people, their families, and communities, today announces the appointment of Dr Arup Paul as its Clinical Director. Dr Paul, who joins from AXA Health where he was Deputy Chief Medical Officer, will be responsible for galvanising LovedBy’s clinical direction as it moves to become a leading provider of global Gen Z healthcare.

  • Hemab Appoints Mads Behrndt as Chief Financial Off

    Hemab Appoints Mads Behrndt as Chief Financial Officer

    • 22 Sep 2021
    • Editor

    Hemab ApS (“Hemab”), a biotech company developing next generation therapeutics for serious underserved bleeding and thrombosis disorders, today announces the appointment of Mads Behrndt as Chief Financial Officer.